Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAL-MPE1
- Development stage
- Phase 1
- Lead developer
- HAL Allergy
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
HAL-MPE1 is a chemically modified, aluminum hydroxide-adsorbed peanut extract developed as a subcutaneous immunotherapy (SCIT) for the treatment of peanut allergy. It is designed to modulate the immune response in individuals with peanut hypersensitivity by reducing IgE binding and allergic symptoms compared to unmodified peanut extracts. The drug acts as an **immunomodulator** and has been evaluated in phase 1 clinical trials for safety and tolerability in both adults and children with peanut allergy. Developed by HAL Allergy Holding BV, it represents an investigational approach aiming to provide causal therapy for food allergies through allergen-specific desensitization[1][3][5][6].
- Other names
- Peanut allergy immunotherapy - HAL AllergyPeanut allergy vaccine - HAL AllergyPeanut extract - HAL Allergy
Beyond the preview
Go deeper on HAL-MPE1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAL-MPE1.